Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 91 results.
User Information
Export Records
  1. 1.   Supplementation with alpha-Tocopherol or beta-Carotene Reduces Serum Concentrations of Vascular Endothelial Growth Factor-D, but Not -A or -C, in Male Smokers
  2. Mondu, A. M.; Rager, H. C.; Kopp, W.; Virtamo, J.; Albanes, D.
  3. Journal of Nutrition. 2011, Nov; 141(11): 2030-2034.
  1. 2.   Faithful Markers of Circulating Cancer Stem Cells: Is CD133 Sufficient for Validation in Clinics?
  2. Crea, F.; Fornaro, L.; Masi, G.; Falcone, A.; Danesi, R.; Farrar, W.
  3. Journal of Clinical Oncology. 2011, Sep; 29(25): 3487-3488.
  1. 3.   Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102
  2. Buchanan, I. M.; Scott, T.; Tandle, A. T.; Burgan, W. E.; Burgess, T. L.; Tofilon, P. J.; Camphausen, K.
  3. Journal of Cellular and Molecular Medicine. 2011, Sep; 15(9): 1999-2006.
  1. 4.   S100A4-induced cell motility and metastasis is restricted by the Wnt/beta-catenin pathway inhibitor calcimycin in colon cancer cells
  2. Sack, U.; Walther, W.; Scudiero, D.; Selby, M.; Aumann, J.; Lemos, C.; Fichtner, I.; Schlag, P. M.; Shoemaker, R. H.; Stein, U.
  3. Molecular Biology of the Cell. 2011, Sep; 22(18): 3344-3354.
  1. 5.   Pharmacogenomics and cancer stem cells: a changing landscape?
  2. Crea, F.; Duhagon, M. A.; Farrar, W. L.; Danesi, R.
  3. Trends in Pharmacological Sciences. 2011, Aug; 32(8): 487-494.
  1. 6.   Identification of an Inhibitor of the EWS-FLI1 Oncogenic Transcription Factor by High-Throughput Screening
  2. Grohar, P. J.; Woldemichael, G. M.; Griffin, L. B.; Mendoza, A.; Chen, Q. R.; Yeung, C.; Currier, D. G.; Davis, S.; Khanna, C.; Khan, J.; McMahon, J. B.; Helman, L. J.
  3. Journal of the National Cancer Institute. 2011, Jun; 103(12): 962-978.
  1. 7.   A novel high-affinity human monoclonal antibody to mesothelin
  2. Ho, M.; Feng, M. Q.; Fisher, R. J.; Rader, C.; Pastan, I.
  3. International Journal of Cancer. 2011, May; 128(9): 2020-2030.
  1. 8.   Chromatographic methods for the quantification of free and chelated gadolinium species in MRI contrast agent formulations
  2. Clevel, D.; Long, S. E.; Sander, L. C.; Davis, W. C.; Murphy, K. E.; Case, R. J.; Rimmer, C. A.; Francini, L.; Patri, A. K.
  3. Analytical and Bioanalytical Chemistry. 2010, Dec; 398(7-8): 2987-2995.
  1. 9.   Modulation of stress genes expression profile by nitric oxide-releasing aspirin in Jurkat T leukemia cells
  2. Nath, N.; Chattopadhyay, M.; Kodela, R.; Tian, S.; Vlismas, P.; Boring, D.; Crowell, J. A.; Kashfi, K.
  3. Biochemical Pharmacology. 2010, Jun; 79(12): 1759-1771.
  1. 10.   Sleeping Beauty-Mediated Somatic Mutagenesis Implicates CSF1 in the Formation of High-Grade Astrocytomas
  2. Bender, A. M.; Collier, L. S.; Rodriguez, F. J.; Tieu, C.; Larson, J. D.; Halder, C.; Mahlum, E.; Kollmeyer, T. M.; Akagi, K.; Sarkar, G.; Largaespada, D. A.; Jenkins, R. B.
  3. Cancer Research. 2010, May; 70(9): 3557-3565.
  1. 11.   Recent Advances from the National Cancer Institute Alliance for Nanotechnology in Cancer
  2. Farrell, D.; Alper, J.; Ptak, K.; Panaro, N. J.; Grodzinski, P.; Barker, A. D.
  3. Acs Nano. 2010, Feb; 4(2): 589-594.
  1. 12.   Increased Expression of Annexin A3 Is a Mechanism of Platinum Resistance in Ovarian Cancer
  2. Yan, X. D.; Yin, J.; Yao, H. Y.; Mao, N.; Yang, Y. L.; Pan, L. Y.
  3. Cancer Research. 2010, Feb; 70(4): 1616-1624.
  1. 13.   Stabilization of the Nitric Oxide (NO) Prodrugs and Anticancer Leads, PABA/NO and Double JS-K, through Incorporation into PEG-Protected Nanoparticles
  2. Kumar, V.; Hong, S. Y.; Maciag, A. E.; Saavedra, J. E.; Adamson, D. H.; Prud'homme, R. K.; Keefer, L. K.; Chakrapani, H.
  3. Molecular Pharmaceutics. 2010, Jan-Feb; 7(1): 291-298.
  1. 14.   HTLV-1 uses HSPG and neuropilin-1 for entry by molecular mimicry of VEGF(165)
  2. Lambert, S.; Bouttier, M.; Vassy, R.; Seigneuret, M.; Petrow-Sadowski, C.; Janvier, S.; Heveker, N.; Ruscetti, F. W.; Perret, G.; Jones, K. S.; Pique, C.
  3. Blood. 2009 113(21): 5176-5185.
  1. 15.   Targeting and Insertion of the Cholesterol-Binding Translocator Protein into the Outer Mitochondrial Membrane
  2. Rone, M. B.; Liu, J.; Blonder, J.; Ye, X. Y.; Veenstra, T. D.; Young, J. C.; Papadopoulos, V.
  3. Biochemistry. 2009 48(29): 6909-6920.
  1. 16.   Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells
  2. Sei, S.; Mussio, J. K.; Yang, Q. E.; Nagashima, K.; Parchment, R. E.; Coffey, M. C.; Shoemaker, R. H.; Tomaszewski, J. E.
  3. Molecular Cancer. 2009 8 AR 47
  1. 17.   ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC
  2. Stockwin, L. H.; Yu, S. X.; Stotler, H.; Hollingshead, M. G.; Newton, D. L.
  3. Bmc Cancer. 2009 9(63): 1-13.
  1. 18.   Photo-activation of the hydrophobic probe iodonaphthylazide in cells alters membrane protein function leading to cell death
  2. Viard, M.; Garg, H.; Blumenthal, R.; Raviv, Y.
  3. BMC Cell Biology. 2009 10 AR 21
  1. 19.   Flavonoid intake and risk of pancreatic cancer in male smokers (Finland)
  2. Bobe, G.; Weinstein, S. J.; Albanes, D.; Hirvonen, T.; Ashby, J.; Taylor, P. R.; Virtamo, J.; Stolzenberg-Solomoni, R. Z.
  3. Cancer Epidemiology Biomarkers & Prevention. 2008 17(3): 553-562.
  1. 20.   Productively combining proteasome inhibition with the immunotherapy of cancer
  2. Sayers, T.
  3. Journal of Molecular Medicine-jmm. 2008 86(8): 857-860.
  1. 21.   Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-Delta 24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer
  2. Page, J. G.; Tian, B. H.; Schweikart, K.; Tomaszewski, J.; Harris, R.; Broadt, T.; Polley-Nelson, J.; Noker, P. E.; Wang, M. H.; Makhija, S.; Aurigemma, R.; Curiel, D. T.; Alvarez, R. D.
  3. American Journal of Obstetrics and Gynecology. 2007, Apr; 196(4):
  1. 22.   Anti-tumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces single-strand breaks and DNA-protein cross-links in sensitive MCF-7 breast cancer cells
  2. Brantley, E.; Antony, S.; Kohlhagen, G.; Meng, L. H.; Agama, K.; Stinson, S. F.; Sausville, E. A.; Pommier, Y.
  3. Cancer Chemotherapy and Pharmacology. 2006, Jul; 58(1): 62-72.
  1. 23.   A model of drug delivery to normal and cancer cells by anti body-targeted nanoliposomes
  2. Sidorov, I. A.; Blumenthal, R.; Dimitrov, D. S.
  3. Journal of Computational and Theoretical Nanoscience. 2006, Jun; 3(3): 405-411.
  1. 24.   Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors
  2. Khan, T.; Stauffer, J. K.; Williams, R.; Hixon, J. A.; Salcedo, R.; Lincoln, E.; Back, T. C.; Powell, D.; Lockett, S.; Arnold, A. C.; Sayers, T. J.; Wigginton, J. M.
  3. Journal of Immunology. 2006, MAY 15; 176(10): 6302-6312.
  1. 25.   Sleeping beauty: a novel cancer gene discovery tool
  2. Dupuy, A. J.; Jenkins, N. A.; Copeland, N. G.
  3. Human Molecular Genetics. 2006, Apr; 15: R75-R79.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel